Not specifically but you can look at their financials and see that they do outsource to these types of consultants (I think most healthcare companies do). Probably mostly in relation to 2RT reimbursement and FDA approval, but I am sure some of the funds spent were in relation to 2RT. Would be unusual for a company to not have advisors involved in a process like this.
Not specifically but you can look at their financials and see...
-
- There are more pages in this discussion • 1,839 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EYE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.0¢ |
Change
0.010(5.56%) |
Mkt cap ! $43.52M | |||
| Open | High | Low | Value | Volume |
| 18.5¢ | 19.5¢ | 18.5¢ | $12.62K | 66.11K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 49388 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 63159 | 2 |
View Market Depth
| Last trade - 12.20pm 18/10/2024 (20 minute delay) ? |
| EYE (ASX) Chart |